Weight-loss drugs help people shed weight, protecting them from strokes and heart attacks. But many people gain weight again after stopping taking GLP-1 receptor agonists such as semaglutide (including trade names Ozempic and Wegovy) and tirzepatide (Mounjaro).
For type 2 diabetes patients, the risk of serious cardiovascular events and death increases significantly once they stop treatment, according to a study published in The Lancet Regional Health Europe.
About 80,000 people with type 2…
Source Link
Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
